ArticleDiabetes/metabolism research and reviews2026
Glycaemic Status Modifies the Association Between Cardiometabolic Index and Cardio-Kidney Outcomes: A Multi-Cohort Analysis.
Article in Diabetes/metabolism research and reviews, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Glycaemic Status Modifies the Association Between Cardiometabolic Index and Cardio-Kidney Outcomes: A Multi-Cohort Analysis.Diabetes/metabolism research and reviews · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
aimsThis multi-cohort study evaluated whether the cardiometabolic index (CMI)-a composite of waist-to-height ratio and triglyceride-to-HDL cholesterol ratio-serves as an early predictor of cardio-kidney risk and whether its predictive value varies across glycaemic states.
methodsWe analysed 327,902 adults in the UK Biobank to examine the association of CMI with baseline cardio-kidney comorbidities, incident cardio-kidney events (CKE)-defined as the composite occurrence of cardiovascular and chronic kidney outcomes, and mortality. Baseline comorbidities was assessed using logistic regression, and Cox models with stratified analyses and restricted cubic splines (RCS) evaluated prospective associations. Findings were externally validated in CHARLS and NHANES. Machine-learning survival models further assessed predictive performance.
resultsHigher CMI was associated with baseline cardio-kidney comorbidities (OR 2.25, 95% CI 2.10-2.42). Among 303,113 participants free of cardiovascular and/or kidney disease at baseline, CMI predicted incident CKE (HR 2.18, 95% CI 2.01-2.38; median follow-up 14.3 years), all-cause death (HR 1.10, 95% CI 1.06-1.14; 15.8 years), and cardio-kidney death (HR 1.55, 95% CI 1.37-1.76; 15.8 years). The strength of associations was greatest in normoglycemia and progressively attenuated in prediabetes and diabetes. RCS analyses revealed nonlinear dose-response relationships, with steep increases in CKE and cardio-kidney mortality below CMI thresholds (∼0.70 and ∼0.95) and more gradual rises thereafter. Results were directionally consistent in external cohorts, particularly for cardio-kidney comorbidities and incident CKE. ML models demonstrated strong discrimination and consistently ranked CMI among the top predictors of incident CKE.
conclusionsCMI is a simple, robust predictor of cardio-kidney risk especially in earlier metabolic states, with particularly strong prognostic value in normoglycaemic individuals where excess risk appears at lower CMI levels.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.